PubRank

Jack Hirsh

Author PubWeight™ 109.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 7.94
2 A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003 6.57
3 Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 5.79
4 Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006 5.69
5 Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010 4.73
6 Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 3.81
7 The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 3.75
8 The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med 2010 3.47
9 Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011 3.28
10 Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 3.14
11 Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011 2.65
12 American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003 2.52
13 American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009 2.13
14 Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 1.97
15 Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003 1.75
16 Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 1.74
17 An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003 1.70
18 American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003 1.67
19 Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011 1.56
20 Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002 1.55
21 Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial. Thromb Haemost 2008 1.50
22 Translational success stories: development of direct thrombin inhibitors. Circ Res 2012 1.49
23 Guidelines for anticoagulant use in acute coronary syndromes. Lancet 2008 1.49
24 Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005 1.49
25 Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol 2009 1.46
26 Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 1.39
27 Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 2003 1.36
28 Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004 1.34
29 Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 1.34
30 Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 2008 1.33
31 Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 1.31
32 New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 1.21
33 Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003 1.08
34 Establishing an optimal therapeutic range for coumarins: filling in the gaps. Arch Intern Med 2004 1.07
35 The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. Transfusion 2012 1.03
36 Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006 0.93
37 Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med 2003 0.92
38 Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003 0.90
39 Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 2013 0.89
40 Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines. Chest 2008 0.88
41 Electrical foot stimulation and implications for the prevention of venous thromboembolic disease. Thromb Haemost 2002 0.86
42 New antithrombotic agents--insights from clinical trials. Nat Rev Cardiol 2010 0.84
43 Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 2004 0.83
44 In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002 0.82
45 Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. Circulation 2009 0.82
46 New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 0.82
47 Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol 2013 0.81
48 New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014 0.81
49 Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. J Thorac Cardiovasc Surg 2012 0.80
50 New oral anticoagulants: not quite there yet. Pol Arch Med Wewn 2009 0.79
51 Diagnosis and treatment of venous thromboembolism. Annu Rev Med 2002 0.79
52 Aspirin response variability after major orthopedic surgery. Thromb Res 2012 0.79
53 Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost 2014 0.78
54 Perioperative management of patients receiving oral anticoagulants. Arch Intern Med 2003 0.78
55 Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. Am Heart J 2007 0.77
56 Electrical foot stimulation: a potential new method of deep venous thrombosis prophylaxis. Vascular 2010 0.77
57 Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis 2007 0.77
58 Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. Chest 2015 0.77
59 Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol 2012 0.77
60 A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. J Thromb Thrombolysis 2015 0.76
61 Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. Future Cardiol 2014 0.76
62 Anticoagulation for venous thromboembolism. BMJ 2007 0.76
63 Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. J Thromb Thrombolysis 2012 0.76
64 Randomized trial of warfarin nomograms. Ann Intern Med 2004 0.76
65 Review: extended out-of-hospital prophylaxis with heparin prevents deep venous thrombosis in elective hip arthroplasty. ACP J Club 2002 0.75
66 Dabigatran: ready for prime time? Pol Arch Med Wewn 2010 0.75
67 Heparin Side Effects-Reply. Arch Intern Med 1984 0.75
68 Duration of anticoagulant therapy for venous thromboembolism. Med J Aust 2009 0.75
69 Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. Thromb Haemost 2013 0.75
70 Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. Thromb Haemost 2015 0.75
71 [Expert consensus document on the use of antiplatelet agents]. Rev Esp Cardiol 2004 0.75
72 Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model. Blood 2010 0.75